Drug Trial Radar · NCT04999969
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
126
Actual
Start
Dec 10, 2021
Primary completion
Oct 7, 2024
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Conditions
- Locally Advanced or Metastatic Solid Tumours
Interventions
AZD0171Drug
AZD0171
DurvalumabDrug
Durvalumab
GemcitabineDrug
Chemotherapy (Standard-of-Care)
Nab-paclitaxelDrug
Chemotherapy (Standard-of-Care)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs)Time frame: From Cycle 1 Day 1 (each cycle was 28 days in length) until Day 90 (post last dose of study intervention), up to 34 months
- Overall Survival at 12 Months (OS-12)Time frame: At 12 months
Locations
34 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Ventura, California
Research Site
Atlanta, Georgia
Research Site
Coeur d'Alene, Idaho
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Buffalo, New York
Research Site
New York, New York
Research Site
Portland, Oregon
Research Site
San Antonio, Texas
Research Site
Charlottesville, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Barrie, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Seongnam-si, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Badalona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Majadahonda, Spain
Research Site
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.